SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.

[1]  Yin-kun Liu,et al.  Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness , 2010, Oncogene.

[2]  Jun Li,et al.  Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor*♦ , 2010, The Journal of Biological Chemistry.

[3]  B. O’Malley,et al.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family , 2009, Nature Reviews Cancer.

[4]  P. Saha,et al.  Absence of the SRC-2 Coactivator Results in a Glycogenopathy Resembling Von Gierke's Disease , 2008, Science.

[5]  Mark J. Murphy,et al.  C‐Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia , 2008, Hepatology.

[6]  J. Reddy,et al.  Redundant enhancement of mouse constitutive androstane receptor transactivation by p160 coactivator family members. , 2007, Archives of biochemistry and biophysics.

[7]  E. Fernandez,et al.  Thermodynamic characterization of the interaction between CAR-RXR and SRC-1 peptide by isothermal titration calorimetry. , 2007, Biochemistry.

[8]  L. D. White,et al.  The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. , 2006, Molecular endocrinology.

[9]  L. Stanley,et al.  PXR and CAR: Nuclear Receptors which Play a Pivotal Role in Drug Disposition and Chemical Toxicity , 2006, Drug metabolism reviews.

[10]  D. Moore,et al.  Gadd45β is induced through a CAR‐dependent, TNF‐independent pathway in murine liver hyperplasia , 2005, Hepatology.

[11]  S. Surapureddi,et al.  Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Kim,et al.  Characterization of activating signal cointegrator-2 as a novel transcriptional coactivator of the xenobiotic nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.

[13]  D. Moore,et al.  Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.

[14]  J. Locker,et al.  Aging does not reduce the hepatocyte proliferative response of mice to the primary mitogen TCPOBOP , 2004, Hepatology.

[15]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[16]  Jianming Xu,et al.  Review of the in vivo functions of the p160 steroid receptor coactivator family. , 2003, Molecular endocrinology.

[17]  D. Concas,et al.  A common set of immediate‐early response genes in liver regeneration and hyperplasia , 2003, Hepatology.

[18]  Fen Wang,et al.  Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. , 2002, The American journal of pathology.

[19]  D. Moore,et al.  Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.

[20]  J. Kemper,et al.  Glucocorticoid Receptor-interacting Protein 1 Mediates Ligand-independent Nuclear Translocation and Activation of Constitutive Androstane Receptor in Vivo * , 2002, The Journal of Biological Chemistry.

[21]  D. Moore,et al.  The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism , 2000, Nature.

[22]  D. Moore,et al.  The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR , 2000, Molecular and Cellular Biology.

[23]  T. Kawamoto,et al.  Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene , 1999, Molecular and Cellular Biology.

[24]  C. Glass,et al.  Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.

[25]  F. Cerignoli,et al.  Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP , 1997, Oncogene.

[26]  D W Nebert,et al.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Azároff,et al.  Phenobarbital induction of cytochrome P-450 gene expression. , 1992, The Biochemical journal.